LIFEWARD LTD
LFWDNASDAQTrading Snapshot
- Day Range
- $6.82 – $7.00
- 52-Week Range
- $4.14 – $10.20
- Volume
- $3.23B
- Avg Volume
- $3.75B
- Shares Outstanding
- 1.6M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $22M
- Last Q Revenue
- $7M
- P/E Ratio
- -0.4
- P/S Ratio
- 0.5x
- EPS (TTM)
- $-11.02
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +102.7%
Why Investors Own LFWD
- ✓High-growth profile — revenue up +46.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LIFEWARD LTD
LFWD
StockOtter · stockotter.spaceAbout LIFEWARD LTD
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Peer-Reviewed Study of Lifeward's ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept.
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
Experienced leadership team to build on established commercial platform and accelerate Lifeward's next phase of growth with continuity of strategy Experienced leadership team to build on established commercial platform a
Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to a loss of $6.96 per share a year ago.
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support con tinued commercial execution HUDSON
Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neuror